Biomarkers Of CRP, IL-6, And D-dimer Covid-19 Patients That Are Giving Convalence Plasma Therapy – Literature Review
Keywords:D-Dimer level, Interleukin 6 (IL-6) level, C-Reactive protein (CRP) level, plasma konvalesen, dan outcomes pasien COVID-19.
Background: Convalescent plasma therapy is the only antibody-based therapy used to treat COVID-19 Patients. The use of convalescent plasma therapy has been recommended by the Food and Drug Administration (FDA) as a therapy for COVID-19 patients (FDA in Asep, 2020). Several routine biomarker parameters used as indicators in the diagnosis of COVID-19 are CRP, IL-6 and D-Dimer. There was a change between the three biomarker values of CRP, IL-6, and D-Dimer between COVID-19 patients on convalescent plasma therapy and COVID-19 patients who did not receive convalescent plasma therapy. This review article is how effective the use of convalescent plasma as therapy for COVID-19 patients is by looking at changes in the biomarkers of CRP, IL-6 and D-Dimer in patients receiving convalescent plasma therapy.
Methode: This literature review uses 3 fulltext articles obtained by combining keywords in an electronic database: Scopus, Cochrane Library, PubMed, and Google Scholar. Articles were eliminated using predefined inclusion and exclusion criteria, then analyzed systematically. The preparation of the discussion uses a systematic analysis based on the themes and topics of discussion obtained in the research article.
Conclussions: There were changes in the biomarker values of CRP, IL-6 and D-Dimer in COVID-19 patients who received convalescent plasma therapy and COVID-19 patients who did not receive convalescent plasma therapy.
Keywords: D-Dimer level, Interleukin 6 (IL-6) level, C-Reactive protein (CRP) level, plasma konvalesen, dan outcomes pasien COVID-19
Elham Roshandel, Ghazaleh Sankanian, Maryam Salimi, et al. 2021. Plasma Exchange followed by convalescent plasma transfusion in COVDI-19 patients. Elsevier.
Fan Wu, et al, 2020. Neutralizing Antiboy Responses to SARS-CoV in a COVID-19 Recovered Patient Cohort and Their Implication: Fudan University School of Basic Medical Science China.
Haithani, Apriadeny, 2021. Korelasi NEWS 2 dan Biomarker Inflamasi NLR, CRP, IL-6 Terhadap Derajat Penyakit Pasien Covid-19 di RSUP Haji Adam Malik Medan. http://repositori.usu.ac.id/handle/123, 56789/36432 Accessed on 10 Agustus 2021 13.18 WIB.
Hu, Xingsheng, Chunhong Hu1, Dixuan Jiang, Qian Zuo, Ya Li, Yang Wang, and Xiangyu Chen. 2020. Effectiveness of Convalescent Plasma Therapy for COVID-19 Patients in Hunan, China. An International Journal. Pp:1-12.
Ji, F., Liu, W., Hao, D-A., Cheng, J et al. 2020. Use of Convalescent Plasma Therapy in Eight Individuals With Mild COVID-19. New Microbes and New Infections. Vol.39: 1-7.
Kahar, Hartono dan Salim, Nabil. 2021. Kelainan Hemostasis pada Pasien COVID-19. UM Proceeding 2021. http://220.127.116.11/index.php/Pro/a rticle/viewFile/7843/3699 Accessed on 10 Agustus 2021 14.45 WIB.
Knopman JM, Krey LC, Oh C, et al. 2014. What Makes Them Split? Identifying Risk Factors That Lead To Franchini, Massimo, MD; Claudia Glingani, BSc, et al. 2020. Safety and efficacy of Convalescent Plasma in Elderly COVID-19 Patiente: The RESCUE Trial. Elsevier. Vol:5:21 pp. 403- 412.
Ling, Li., Wei, Zhang., Yu, Hu., Xunliang, Tong., Lili, Ren et al. 2021. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life- Threatening COVID-19: A Randomized Clinical Trial. JAMA Vol. 324(5): 460-470.
Permana, Atna., Yari, Cut Ervinar., Aditya, Alaika Kurnia. 2021. Gambaran D- Dimer dan Limfosit Pada Pasien Terkonfirmasi COVID-19 di RS Haji Jakarta. Anakes: Jurnal Ilmiah Analis Kesehatan. Vol 7(1): 62-71.
Rostami, Mehrdad dan Mansouritorghabeh, Hassan. 2020. D-Dimer Level in COVID-19 Infectionm: A Systematic Review. Expert Review of Hematology. Vol. 13(11):1265-1275.
Sukohar, Asep dan Zetira, Zihan. 2020. Manfaat Terapi Plasma Konvalesen pada Infeksi COVID-19. Medula. Vol10(2): 333-340.
World Health Organization. Weekly Epidemilogical Update, Coronavirus Disease 2019 (COVID-19). Medica Hospitalia: Journal of Clinical Medicine.
How to Cite
Copyright (c) 2022 yekti Tunjungsari
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.